This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Imuracetam
Imuracetam is an abandoned 1970s racetam development candidate from UCB Pharma (developmental code UCB-G218).
Aliases (2)
Overview
What is Imuracetam?
Imuracetam is an obscure, lightly characterized member of the racetam family. There are no published human pharmacokinetic or efficacy trials, and it is not commercially marketed.
Key Benefits
Reported preclinically to share the broad cognitive and neuroprotective profile of other racetams (memory, attention), but no human evidence supports specific benefit claims.
Mechanism of Action
Presumed to share the racetam-class mechanism: modulation of AMPA receptors, indirect cholinergic facilitation, and membrane fluidity effects. Specific binding affinities and CNS penetration are not well characterized.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
References
Wikipedia — Imuracetam
confirms UCB-G218 developmental code, 1970s development, never marketed; stub-class article reflecting absence of literature
View StudyPubMed search for "imuracetam"
returns zero direct results; auto-redirects to dimiracetam (unrelated compound)
View StudyMedsafe NZ — Classification status of racetams
regulatory survey listing imuracetam alongside other racetams for completeness; no clinical data
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.